Bayer PI3K inhibitors identified by FDA as breakthrough therapy for treatment of lymphoma

According to the World Cancer Research Foundation (WCRF), non-Hodgkin lymphoma (NHL) is the most common blood cancer in the world, accounting for 3% of all cancer patientsAccording to the American Cancer Society, more than 74,000 people will be diagnosed with the NHL in 2019, and about 20,000 will die as a resultinert non-Hodgkin's lymphoma (iNHL) is an NHL type characterized by slow progression and diffusionThe two most common forms of iNHL are folllylyumlymphoma (FL) and MZL, accounting for 20% and 10% of NHL patients, respectivelyAlthough NHL patients respond well to the initial treatment, their condition is usually accompanied by multiple relapses, with the remission period shorter and shorter after each relapseAdvanced NHL patients often need systemic chemical immunotherapy, and they urgently need new effective treatments to relieve disease and prolong their livesAliqopa, developedBayer, is an intravenous phosphatidyl inositol-3-kinase inhibitorPreclinical studies have shown that Aliqopa is able to inhibit pi3K-alpha and PI3K-xenon, two kinase subtypes, which are mainly expressed in malignant B cells at the sub-nanomolar levelThe PI3K signaling pathway is important in cell growth, survival, and metabolism, and the loss of control of this signaling pathway can easily trigger NHLAliqopa induces tumor cell death and inhibits the proliferation of primary malignant B cellsAliqopa inhibits several key cellular signaling pathways, including B-cell receptor (BCR) signal transduction, CXCR12-mediated malignant B-cell kineticization, and NF-B signal transduction in lymphoma cell linesAliqopa was awarded an FDA-issued orphan drug in 2015 and 2017 for the treatment of FL and MZL, respectivelyIt was approved in September 2017 for accelerated approval to treat adult patients with recurrent FL and have undergone systemic therapy at least twicethe mechanism of action of Aliqopa: double inhibition PI3K-alpha and PI3K-xenon two kinase subtypes, blocking signal conduction (photo source: Aliqopa official website)the issuance of this breakthrough therapy is based on the positive results of the phase 2 trial CHRONOS-1Preliminary results showed that the total remission rate (ORR) of the MZL subgroup, which had previously received at least two treatments, was 69.6%, compared with 59.2% for the all-iNHL group"Clinical data show that Aliqopa may present a new treatment option for patients with recurrent MZL who have unmet needs," said DrScott ZFields, Senior Vice President and Head of Oncology Development,Bayer PharmaceuticalsBayer looks forward to working closely with the FDA to bring Aliqopa to MZL patients as soon as possible"References:Bayer Receives U.SFDA Make Therapy Age for Aliqopa™ (copanlisib) for the Treatment of Zone LymphomaRetrieved May, 29, 2019, from https://Courier- Retrieved May, 29, 2019, from https://mp.weixin.qq.com/s/wXQcYvesiyrtZbvx1OccNA2017 10th anti-cancer drug available! Bayer's new drug was approved by the FDA todayRetrieved May, 29, 2019, from https://mp.weixin.qq.com/s/psv0ziEDDnBKbsEXPc-suANature Depth Review: What innovative therapies are worth paying attention to for the most common blood cancers? Retrieved May, 29, 2019, from https://mp.weixin.qq.com/s/GOE95oHepFjKi6KHQGKQewExpressSpecific target PI3K subtype, lymphoma therapy recognized by FDA Breakthrough Therapy Retrieved May, 29, 2019, from https://mp.weixin.qq.com/s/RGaDaCugOIYqElFY5tsJYQ Original title: Courier- and Bayer PI3K Inhibitors Identified by FDA Breakthrough Therapy for Treatment of Lymphoma